Key Highlights
- AI-Powered Imaging Milestone: Median Technologies presents its cutting-edge AI imaging platform and services, positioned to elevate oncology trials globally.
- New Radiopharmaceutical Solution Revealed: Company debuts a specialized solution to accelerate radiopharmaceutical image processing for advanced cancer research.
- Strong Global Footprint at ASCO: With two scientific abstracts and live sessions, Median strengthens its global presence among 35,000 oncology professionals.
AI-Powered Innovation in Oncology Imaging
Median Technologies, a pioneer in AI-driven medical imaging, will showcase its eyonis® Software as a Medical Device (SaMD) and iCRO imaging services at ASCO 2025, held from May 30 to June 2 in Chicago. Designed to transform oncology trials, the company’s solutions integrate machine learning and radiological data to deliver faster, earlier, and more reliable insights in cancer therapy development.
Exclusive Showcases and Live Demonstrations at Booth #11046
At Booth #11046, South Building, Hall A, Median will provide interactive demonstrations of its latest AI-powered imaging solutions between May 31 and June 2. Visitors will discover how the company’s technology is driving improvements in patient stratification, tumor response monitoring, and clinical decision-making across oncology trials of all sizes.
Debut of AI Radiopharmaceutical Imaging Technology
Median will host two engaging booth presentations on May 31 and June 1 (11:30 am to 12:00 pm CT), unveiling its new radiopharmaceutical image processing solution. The sessions aim to illustrate how this innovation is enhancing data accuracy and speed in trials involving advanced nuclear medicine therapies—signaling a significant leap forward for precision oncology.
Scientific Recognition and Research Validation
The company’s expertise is underscored by two accepted ASCO abstracts now available online: Abstract e24073 demonstrates the technical reliability of the L3 Skeletal Muscle Index in CT, while Abstract e13590 introduces predictive endpoints using tumor growth modeling and informed neural networks. These peer-reviewed publications position Median as a scientific leader in AI imaging for clinical trials.
About Median Technologies
Median Technologies (FR0011049824, ALMDT) develops innovative imaging solutions powered by artificial intelligence to support oncology clinical trials and early cancer diagnosis. Its offerings include iCRO, a central imaging platform for drug development, and eyonis®, a next-generation AI-based Software as a Medical Device (SaMD). With a presence in France, the United States, and China, Median empowers biopharmaceutical companies and clinicians to enhance patient care and accelerate innovation. Learn more at www.mediantechnologies.com.
By